Shield Therapeutics Preps for Phase III with Anemia Drug
By Nuala Moran
Friday, November 15, 2013
LONDON – Shield Therapeutics Ltd. is awaiting FDA permission for a Phase III trial of its oral iron replacement, ST10, for treating anemia in patients with chronic kidney disease (CKD) who are not on dialysis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.